New Aspects of Tyrosine Kinase Inhibitors

In this second video on refractory thyroid cancer, Marcia Brose, MD, reviews recent findings from clinical practice and evolving clinical trials in the context of tyrosine kinase inhibitor therapy for refractory thyroid cancer. Among the subjects Dr. Brose considers are the addition of the mTOR inhibitor everolimus to therapy for patients whose disease is progressing on sorafenib, vemurafenib in patients with BRAF V600E-­positive progressive papillary thyroid cancer and the Phase 1 trial of cabozantinib.

 

 

 

Related Links

• Clinical Briefing: Sorafenib for Differentiated Thyroid Cancer
• Case Study: A 37-year-old man with metastatic iodine-nonavid differentiated thyroid cancer
• Dr. Brose’s Profile